Mometasone-eluting resorbable scaffold - 480 Biomedical

Drug Profile

Mometasone-eluting resorbable scaffold - 480 Biomedical

Alternative Names: Mometasone furoate sinus drug depot

Latest Information Update: 11 Nov 2016

Price : $50

At a glance

  • Originator 480 Biomedical
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnadienediols; Skin disorder therapies
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Rhinosinusitis

Most Recent Events

  • 14 Nov 2016 Chemical structure information added
  • 20 Oct 2016 Preclinical trials in Rhinosinusitis in USA (unspecified route) before October 2016
  • 20 Oct 2016 480 Biomedical plans a phase I exploratory trial for Rhinosinusitis (Treatment-experienced) in New Zealand and Australia (NCT02942186)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top